» Articles » PMID: 24199188

Behcet's Disease: Systemic and Ocular Manifestations

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2013 Nov 8
PMID 24199188
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: The aim of this study was to evaluate if patients with Behcet's disease who have ocular involvement have a more severe form of this disease as compared to patients with Behcet's disease alone.

Methods: A total of 99 patients were included in the study. 76 patients were used as part of the examined group, and 23 patients formed a control group.

Results: The following are the results of examined and control groups, respectively: recurrent oral aphthous ulcers 89.5%, 95.7%; genital ulcers 61.8%, 97.0%; articular involvement 72.4%, 65.2%; vasculitis 81.6%, 60.9%; positive pathergy test 25.0%, 47.8%. Higher frequency of genital ulcerations was noted in control group (P = 0.001). More than two major criteria were met in 100% of the cases. HLA B51 was present in 78.9% of the cases in the examined group and 43.5% of the cases in control group; thus there is significant difference between them (P = 0.001). Visual acuity >0.5 occurred in 76% (examined group). Most frequent ocular manifestations in the examined group were retinal periphlebitis 81.6%, periphlebitis and periarteritis 65%, and serofibrinous uveitis 63.2%. Macular edema as a complication was present in 63.2%. The majority of patients (55.3%) were treated with combined therapy consisting of cyclosporine A and systemic corticosteroids. In 38.2% of patients, laser photocoagulation was used on retinal periphery.

Citing Articles

Investigation of optic nerve function in Behçet's patients with optic disc hyperfluorescence in fundus fluorescein angiography.

Sahin A, Batu Oto B, Uzun Adatepe N, Ucar D Int Ophthalmol. 2024; 44(1):76.

PMID: 38351422 DOI: 10.1007/s10792-024-02927-y.


Are optical coherence tomography and fluorescein angiography comparable for detection of macular edema in Behçet uveitis?.

Degirmenci M, Yalcindag F Graefes Arch Clin Exp Ophthalmol. 2023; 261(11):3275-3281.

PMID: 37773289 DOI: 10.1007/s00417-023-06249-0.


Visual outcomes and factors predictive of visual loss in Behcet's disease in Sultan Qaboos University Hospital, Oman.

Al Kharousi N, Alnaabi K, Almahrouqi O, Mal W Oman J Ophthalmol. 2023; 15(3):269-273.

PMID: 36760938 PMC: 9905896. DOI: 10.4103/ojo.ojo_68_22.


MicroRNAs in the regulation of Th17/Treg homeostasis and their potential role in uveitis.

Tang F, Zhou Z, Huang K, Deng W, Lin J, Chen R Front Genet. 2022; 13:848985.

PMID: 36186459 PMC: 9515448. DOI: 10.3389/fgene.2022.848985.


Epidemiology of Ocular Manifestations in Autoimmune Disease.

Glover K, Mishra D, Raghu Raj Singh T Front Immunol. 2021; 12:744396.

PMID: 34795665 PMC: 8593335. DOI: 10.3389/fimmu.2021.744396.


References
1.
Sfikakis P, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A . Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. Rheumatology (Oxford). 2007; 46(5):736-41. DOI: 10.1093/rheumatology/kem034. View

2.
Yazici H, Pazarli H, Barnes C, Tuzun Y, Ozyazgan Y, Silman A . A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med. 1990; 322(5):281-5. DOI: 10.1056/NEJM199002013220501. View

3.
Sakai T, Watanabe H, Kuroyanagi K, Akiyama G, Okano K, Kohno H . Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis. Br J Ophthalmol. 2013; 97(3):338-42. DOI: 10.1136/bjophthalmol-2012-302515. View

4.
Pleyer U, Hazirolan D, Winterhalter S, Stubiger N . [Behçet's disease - ophthalmological and general aspects part I : etiology, pathogenesis and diagnostics]. Ophthalmologe. 2012; 109(11):1129-41. DOI: 10.1007/s00347-012-2698-5. View

5.
Houman M, Neffati H, Braham A, Harzallah O, Khanfir M, Miled M . Behçet's disease in Tunisia. Demographic, clinical and genetic aspects in 260 patients. Clin Exp Rheumatol. 2007; 25(4 Suppl 45):S58-64. View